Prognoza
Średnia cena docelowa analityków wynosi 118,39 € (+1,54%). Mediana wynosi 123,03 € (+5,52%).
| Kupuj |
2 |
| Trzymaj |
12 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Apogee Therapeutics reaches record high at $134.89
Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Więcej na de.investing.com
Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie
Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Więcej na de.investing.com
Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout
Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Więcej na finance.yahoo.com
Apogee Therapeutics reaches record high of $134.34
Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Więcej na de.investing.com
Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie
Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale Apogee Therapeutics osiągnęła przychody w wysokości 0 € i zysk netto w wysokości -75,23 mln €
| (EUR) | czerwiec 2026 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -75,23 mln | 34,15% |
| EBITDA | -73,42 mln | 31,86% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 7,66 mld € |
Liczba akcji | 62,2 mln |
Maksimum/minimum z 52 tygodni | 123,11 € - 32,25 € |
| Dywidendy | Nie |
Beta | 0,34 |
C/Z (PE Ratio) | -31,12 |
PEG (PEG Ratio) | 6,57 |
C/WK (PB Ratio) | 8,53 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Apogee Therapeutics, Inc. działa poprzez swoją spółkę zależną jako firma biotechnologiczna, która opracowuje leki biologiczne do leczenia atopowego zapalenia skóry (AD), przewlekłej obturacyjnej choroby płuc (COPD) oraz powiązanych wskazań zapalnych i immunologicznych. Spółka rozwija przede wszystkim APG777, przeciwciało monoklonalne (mAb) o przedłużonym okresie półtrwania podawane podskórnie (SQ) w leczeniu AD, oraz APG808, przeciwciało monoklonalne o przedłużonym okresie półtrwania podawane podskórnie (SQ) w leczeniu COPD. Jej programy na wcześniejszych etapach badań obejmują APG990, przeciwciało monoklonalne o przedłużonym okresie półtrwania podawane podskórnie (SQ) do leczenia AD, oraz APG222, przeciwciała o przedłużonym okresie półtrwania podawane podskórnie (SQ) w leczeniu AD. Firma została założona w 2022 roku i ma siedzibę w Waltham w stanie Massachusetts.
| Nazwa | Apogee Therapeutics |
| CEO | Michael Thomas Henderson |
| Siedziba | Waltham,
ma Stany Zjednoczone |
| Strona internetowa | |
| Branża | Żywność |
| Debiut giełdowy | 14.07.2023 |
| Pracownicy | 261 |
Deep Dive
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | APGE |